Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy
Status:
Unknown status
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The purpose of our study is to evaluate the efficacy and safety of Lanreotide Autogel in
children with congenital hyperinsulinism already treated with Octreotide by pump.
Congenital hyperinsulinism is a genetic disorder characterized by inappropriate insulin
secretion resulting in persistent hypoglycemia (low blood sugars. Patients exposed to
recurrent hypoglycemic episodes are at increased risk of developmental disorders, so
identification and prompt management of patients are essential. Many patients are treated
with the somatostatin analog Octreotide which is administered by continuous infusion using a
pump (we use an insulin pump). This treatment may pose a huge burden and be stressful for
patients and families as it demands intensive daily care. In an effort to simplify the daily
care of our patients and improve their quality of life we will study the efficacy and safety
of Lanreotide Autogel - a long-acting somatostatin analog that can be administered by
injection once a month